TWST · XBRL financial data

Twist Bioscience financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TWST's year ends in late September)

In millions of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Cost of revenue	61	81	119	155	180	186
Research and development	43	69	120	107	91	80
Selling, general and administrative	103	136	213	190	218	247
Operating income (loss)	(140)	(153)	(235)	(217)	(221)	(136)
Interest income	1	0	3	14	15	11
Interest expense	1	0	0	0	0	—
Other income (expense)	(0)	(1)	(1)	(1)	(3)	(1)
Income tax expense (benefit)	0	(2)	(10)	1	1	1
Net income (loss)	(140)	(152)	(218)	(205)	(209)	(78)
Earnings per share, basic USD per share	(3.57)	(3.15)	(4.04)	(3.60)	(3.60)	(1.30)
Earnings per share, diluted USD per share	(3.57)	(3.15)	(4.04)	(3.60)	(3.60)	(1.30)
Weighted average shares, basic millions of shares	39	48	54	57	58	60
Weighted average shares, diluted millions of shares	39	48	54	57	58	60

Fiscal years (TWST's year ends in late September)

In millions of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Cash and cash equivalents	94	466	379	286	226	183
Short-term investments	196	12	126	50	50	49
Accounts receivable	26	29	40	44	35	57
Inventory	12	32	39	32	24	28
Prepaid and other current assets	6	8	12	12	11	15
Total current assets	335	546	596	424	347	333
Property and equipment, net	25	44	139	132	103	102
Right-of-use asset	34	62	75	72	59	49
Goodwill	1	22	86	86	86	82
Total assets	399	702	961	776	614	642
Accounts payable	5	15	20	14	2	11
Accrued liabilities	4	6	10	11	15	23
Current portion of long-term debt	3	2	0	—	—	—
Total current liabilities	36	63	91	73	71	91
Long-term debt	1	—	—	—	—	—
Lease liability, non-current	25	53	81	79	70	62
Total liabilities	63	121	172	153	142	169
Accumulated deficit	(458)	(611)	(828)	(1,033)	(1,242)	(1,320)
Total stockholders' equity	336	581	789	623	473	473
Total liabilities and equity	399	702	961	776	614	642
Common shares outstanding (cover page) millions of shares	45	50	57	58	59	61

Fiscal years (TWST's year ends in late September)

In millions of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Net income (loss)	(140)	(152)	(218)	(205)	(209)	(78)
Stock-based compensation	17	37	80	30	51	64
Depreciation and amortization	7	10	17	29	31	25
Net cash from operating activities	(142)	(112)	(124)	(142)	(64)	(48)
Purchases of property and equipment	10	27	102	28	5	28
Net cash from investing activities	(115)	156	(233)	51	(3)	(25)
Repayments of long-term debt	3	3	2	0	0	—
Net cash from financing activities	304	329	271	1	7	29
Net change in cash	47	373	(87)	(91)	(60)	(44)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Twist Bioscience	117	not reported	1.1*	62.7M	—	Q3 FY26 10-QJun 30, 2026
Acadia Pharmaceuticals	385	308	101*	172.3M	—	Q2 FY26 10-QJun 30, 2026
Xenon Pharmaceuticals	120	not reported	(95)*	96.8M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Summit Therapeutics	151	not reported	not reported	799.8M	—	Q3 FY26 10-QSep 30, 2026
Cytokinetics	203	48	not reported	139.3M	—	Q3 FY26 10-QSep 30, 2026
TG Therapeutics	483	240	39*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Catalyst Pharmaceuticals	756	149	60	122.4M	—	Q1 FY26 10-QMar 31, 2026
Vericel	125	77	16*	51.2M	—	Q2 FY26 10-QJun 30, 2026
Recursion Pharmaceuticals	550	19	(77)*	622.8M	6.2 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.